CR Bard Gets a Hold Rating from Jefferies

By Ryan Adsit

In a report issued on September 12, Michael Yee from Jefferies reiterated a Hold rating on CR Bard (NYSE: BCR), with a price target of $317. The company’s shares opened today at $319.79, close to its 52-week high of $324.58.

According to, Yee is a 5-star analyst with an average return of 11.3% and a 63.5% success rate. Yee covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Arbutus Biopharma Corporation, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on CR Bard is Hold and the average price target is $317, representing a -0.9% downside.

In a report issued on August 31, BMO Capital also reiterated a Hold rating on the stock with a $317 price target.

CR Bard’s market cap is currently $23.28B and has a P/E ratio of 42.09. The company has a book value ratio of 12.5515.

Based on the recent corporate insider activity of 99 insiders, corporate insider sentiment is negative on the stock. Last month, John Groetelaars, the Group President of BCR sold 23,687 shares for a total of $7,549,758.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

C.R. Bard, Inc. designs, develops, manufactures, distributes and markets medical technologies in the fields of vascular, urology, oncology and surgical specialty products. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.